Menu
← Oncology Approval Tracker
FDA DECISION ·
Clolar
clofarabine · Genzyme / Sanofi
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients ages one through 21 with relapsed or refractory ALL after at least two prior regimens.
LAMPGEN ANALYSIS
Why it matters
The decision converts the previous accelerated approval for this pediatric and young adult population.
What research teams should watch
Retain the historical age and prior-regimen criteria when comparing the original and converted approvals.
PRIMARY RECORDS